Total Payments
$535,159
2024 Payments
$510,650
Companies
16
Transactions
82
Medicare Patients
339
Medicare Billing
$81,295
Payment Breakdown by Category
Consulting$531,830 (99.4%)
Food & Beverage$2,309 (0.4%)
Other$1,000 (0.2%)
Travel$20.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $531,830 | 16 | 99.4% |
| Food and Beverage | $2,309 | 64 | 0.4% |
| Grant | $1,000 | 1 | 0.2% |
| Travel and Lodging | $20.00 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $529,028 | 20 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $2,165 | 3 | $0 (2019) |
| Janssen Biotech, Inc. | $1,010 | 1 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $1,000 | 1 | $0 (2022) |
| GlaxoSmithKline, LLC. | $513.11 | 16 | $0 (2023) |
| Genentech USA, Inc. | $337.91 | 15 | $0 (2019) |
| GENZYME CORPORATION | $272.42 | 3 | $0 (2024) |
| Shire North American Group Inc | $150.00 | 2 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $148.39 | 3 | $0 (2018) |
| CSL Behring | $138.02 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $510,650 | 14 | PFIZER INC. ($510,500) |
| 2023 | $18,576 | 5 | PFIZER INC. ($18,300) |
| 2022 | $1,000 | 1 | SANOFI-AVENTIS U.S. LLC ($1,000) |
| 2021 | $23.81 | 1 | GENZYME CORPORATION ($23.81) |
| 2020 | $1,050 | 3 | Janssen Biotech, Inc. ($1,010) |
| 2019 | $2,731 | 26 | Janssen Scientific Affairs, LLC ($2,165) |
| 2018 | $863.82 | 26 | GlaxoSmithKline, LLC. ($206.99) |
| 2017 | $265.14 | 6 | Genentech USA, Inc. ($146.75) |
All Payment Transactions
82 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $72,900.00 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $71,200.00 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $84,300.00 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $4,600.00 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $13,200.00 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ONCOLOGY | ||||||
| 06/11/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $66,600.00 | General |
| Category: ONCOLOGY | ||||||
| 05/09/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $72,600.00 | General |
| Category: ONCOLOGY | ||||||
| 05/09/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Immunology | ||||||
| 03/26/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: ONCOLOGY | ||||||
| 02/21/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $15,600.00 | General |
| Category: ONCOLOGY | ||||||
| 01/19/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $45,900.00 | General |
| Category: ONCOLOGY | ||||||
| 01/19/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: ONCOLOGY | ||||||
| 01/16/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $60,600.00 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $98.61 | General |
| Category: Immunology | ||||||
| 09/01/2023 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $18,300.00 | General |
| Category: ONCOLOGY | ||||||
| 07/24/2023 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $27.74 | General |
| Category: IMMUNOLOGY | ||||||
| 07/13/2023 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $124.96 | General |
| Category: Immunology | ||||||
| 06/26/2023 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: IMMUNOLOGY | ||||||
| 12/14/2022 | SANOFI-AVENTIS U.S. LLC | — | Grant | Cash or cash equivalent | $1,000.00 | General |
| 03/04/2021 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: Immunology | ||||||
| 03/27/2020 | Janssen Biotech, Inc. | DARZALEX (Biological) | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| Category: Oncology | ||||||
| 01/31/2020 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.47 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 01/08/2020 | OptiNose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 12/04/2019 | OptiNose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 92 | 2,354 | $80,248 | $24,287 |
| 2022 | 3 | 70 | 2,071 | $64,718 | $20,189 |
| 2021 | 4 | 109 | 2,816 | $76,054 | $21,538 |
| 2020 | 3 | 68 | 1,916 | $61,983 | $15,281 |
Total Patients
339
Total Services
9,157
Medicare Billing
$81,295
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 130 | $27,950 | $10,368 | 37.1% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 28 | 2,096 | $35,632 | $8,334 | 23.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $13,950 | $4,649 | 33.3% |
| 95115 | Professional service for single injection of allergen | Office | 2023 | 11 | 97 | $2,716 | $935.30 | 34.4% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 26 | 1,954 | $33,218 | $8,652 | 26.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 90 | $19,350 | $7,602 | 39.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $12,150 | $3,936 | 32.4% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 36 | 2,710 | $46,070 | $11,688 | 25.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 25 | 58 | $12,470 | $4,914 | 39.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 30 | 30 | $13,500 | $4,277 | 31.7% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 18 | 18 | $4,014 | $657.86 | 16.4% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2020 | 25 | 1,824 | $33,576 | $8,004 | 23.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 16 | 65 | $14,707 | $3,857 | 26.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 27 | 27 | $13,700 | $3,420 | 25.0% |
About Dr. Marc Braunstein, MD
Dr. Marc Braunstein, MD is a Allergy & Immunology healthcare provider based in Hewlett, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/23/2013. The National Provider Identifier (NPI) number assigned to this provider is 1215358908.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marc Braunstein, MD has received a total of $535,159 in payments from pharmaceutical and medical device companies, with $510,650 received in 2024. These payments were reported across 82 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($531,830).
As a Medicare-enrolled provider, Braunstein has provided services to 339 Medicare beneficiaries, totaling 9,157 services with total Medicare billing of $81,295. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Other Specialties Allergy
- Location Hewlett, NY
- Active Since 12/23/2013
- Last Updated 07/21/2022
- Taxonomy Code 207K00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1215358908
Products in Payments
- ELREXFIO (Drug) $528,800
- DARZALEX (Biological) $3,175
- NUCALA (Biological) $394.72
- Xolair (Biological) $337.91
- DUPIXENT (Biological) $297.89
- EUCRISA (Drug) $227.74
- Hizentra (Biological) $138.02
- Xhance (Drug) $136.57
- CINRYZE (Drug) $125.00
- FASENRA (Drug) $125.00
- SOLIRIS (Drug) $121.68
- BREO (Drug) $118.39
- XOLAIR (Biological) $26.18
- TAKHZYRO (Biological) $25.00
- STIOLTO RESPIMAT (Drug) $24.54
- SPIRIVA RESPIMAT (Drug) $23.80
- SYMBICORT (Drug) $23.39
- Odactra (Drug) $23.28
- DUPIXENT DUPILUMAB INJECTION (Biological) $15.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.